Smith & Nephew plc (LON:SN) declared a dividend on Wednesday, July 29th, Upcoming.Co.Uk reports. Stockholders of record on Thursday, October 1st will be paid a dividend of $0.14 per share on Wednesday, October 28th. This represents a dividend yield of 0.68%. The ex-dividend date is Thursday, October 1st. The official announcement can be accessed at this link.
Shares of SN opened at GBX 1,619.50 ($19.93) on Thursday. The stock has a 50-day simple moving average of GBX 1,588.72 and a 200-day simple moving average of GBX 1,634.48. The company has a debt-to-equity ratio of 39.82, a quick ratio of 0.96 and a current ratio of 2.06. The stock has a market capitalization of $14.18 billion and a PE ratio of 23.68. Smith & Nephew has a 1 year low of GBX 14.99 ($0.18) and a 1 year high of GBX 2,023 ($24.90).
In related news, insider Roland Diggelmann bought 2,125 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were acquired at an average price of GBX 1,510 ($18.58) per share, with a total value of £32,087.50 ($39,487.45).
Several equities research analysts have recently weighed in on the company. Credit Suisse Group cut their target price on Smith & Nephew from GBX 1,685 ($20.74) to GBX 1,675 ($20.61) and set a “neutral” rating on the stock in a research report on Thursday. Morgan Stanley cut their target price on Smith & Nephew from GBX 1,950 ($24.00) to GBX 1,940 ($23.87) and set an “overweight” rating on the stock in a research report on Thursday. Berenberg Bank cut their target price on Smith & Nephew from GBX 2,150 ($26.46) to GBX 2,090 ($25.72) and set a “buy” rating on the stock in a research report on Thursday. Jefferies Financial Group cut their target price on Smith & Nephew from GBX 2,160 ($26.58) to GBX 1,800 ($22.15) and set a “buy” rating on the stock in a research report on Tuesday, April 28th. Finally, UBS Group reissued a “neutral” rating on shares of Smith & Nephew in a research report on Tuesday, June 23rd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the stock. Smith & Nephew currently has an average rating of “Hold” and a consensus target price of GBX 1,782.25 ($21.93).
About Smith & Nephew
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Further Reading: What sectors are represented in the Hang Seng index?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.